中医药信息2016，Vol.33Issue(1)：95-97,3.
紫茜合剂治疗慢性原发免疫性血小板减少症的临床观察
Clinical Observation on Ziqian Compound for Chronic Primary Immune Thrombocytopenia
摘要
Abstract
Objective:To observe the efficacy of Ziqian compound for chronic primary immune thrombocytope-nia.Methods:Totally 70 patients were randomized into a treatment group ( Ziqian compound +danazol ) and a control group(danazol only),with 35 in each group.The treatment lasted 6 months.The platelet count after treatment was observed in both groups .Results:The total effective rates of the treatment group and control group were 65.71% and 48.57% respectively,with a significant difference between two groups (P<0.05). After treatment,the platelet count in the treatment group was significantly higher than that in the control group . After 6 months, the follow -up efficiencies of the treatment group and control group were 51.43% and 28.57% respectively ,with a significant difference between two groups ( P <0 .05 ) .Conclusion:Ziqian com-pound is effective for chronic primary immune thrombocytopenia ,and it can reduce adverse reactions caused by application of danazol and extend the period in the meanwile .关键词
原发免疫性血小板减少症/慢性/紫茜合剂Key words
Primary immune thrombocytopenia/Chronic/Ziqian compound分类
医药卫生引用本文复制引用
孙凤,倪虹,郝晶..紫茜合剂治疗慢性原发免疫性血小板减少症的临床观察[J].中医药信息,2016,33(1):95-97,3.基金项目
黑龙江省教育厅重点科研项目(No.11531Z14) （No.11531Z14）
